In 1998, human embryonic stem cells were first generated and were expected to contribute greatly to regenerative medicine. However, when medical treatments were performed using human embryonic stem cells, there were problems, such as transplant rejection, as well as bioethical issues. Induced pluripotent stem cells were generated from mouse and human fibroblasts in 2006 and 2007 by introducing four transcription factors (Oct3/4, Sox2, c-Myc and Klf4). This process was defined as direct reprogramming, and induced pluripotent stem cells were better tolerated. Although induced pluripotent stem cells have contributed greatly to biomedical research and regenerative medicine, high tumorigenic potential is still a critical problem due to the introduction of the oncogene c-Myc and reprogramming with a virus vector. To address this, we reprogrammed somatic cells by transfection with microribonucleic acids to avoid using virus vectors for genomic integration into the host genome. We found that it was possible to reprogram mouse and human cells to pluripotency by direct transfection of three mature microribonucleic acids (mir-200c, -302s and -369s) with increased expression levels in embryonic stem cells and induced pluripotent stem cells. The microribonucleic acid-induced pluripotent stem cells have a reduced risk of mutations and tumorigenesis. Our laboratory also introduced four transcription factors (Oct3/4, Sox2, c-Myc and Klf4) into cancer cells, generating induced pluripotent cancer cells that exhibited strikingly less malignant features, suggesting the possibility of a novel type of cancer therapy. However, the gene transduction method is not yet safe for clinical applications, due to a genomic integration that may cause tumor formation. We are currently investigating the reprogramming method using microribonucleic acids in cancer cells to develop a very safe, highly efficient and highly complete reprogramming for clinical applications.
INTRODUCTION
Mouse embryonic stem (ES) cells were first generated in 1981, and many studies tried to determine the molecular mechanisms involved in pluripotency. Human ES cells were generated in 1998 and were determined to be: (i) pluripotent, that is, able to differentiate into every type of cell, structuring the whole body and (ii) able to selfrenew while remaining pluripotent. In previous reports, stem cells were classified into three categories, totipotent, pluripotent and multipotent, depending on their differentiation levels. Pluripotent cells can differentiate into three germ layers, such as ES cells. Totipotent cells have the ability to differentiate into extraembryonic tissues such as the placenta and trophoblast, in addition to being pluripotent. A fertilized egg and an egg cell that has undergone nuclear transplant are totipotent. Multipotent cells are tissue stem cells and can only differentiate into specific tissue cells.
A clinical trial examining ES cells differentiating into nerve cells for the treatment of spinal cord injuries started in the USA in 2010. Great advances were expected in the field of regenerative medicine; however, there were some problems with medical treatments involving human ES cells. First, there is a bioethical issue because a fertilized egg is used to generate ES cells. In addition, when ES cells are applied to an organ in regenerative medicine, the recipients must be given an immunosuppressant drug to prevent transplant rejection and few cells may take.
The use of induced pluripotent stem (iPS) cells solved the problems mentioned above. In 2006, iPS cells were generated from mouse embryonic fibroblasts (MEF) (1) . They were then generated from human dermal fibroblasts the following year (2) . The iPS cells are reprogrammed from differentiated somatic cells by going back to an undifferentiated state similar to ES cells. Both ES cells and iPS cells are defined as pluripotent and are able to differentiate into three germ layers (endoderm, mesoderm and ectoderm) as well as self-renew. The induction of iPS cells was confirmed by gene expression analyses and the formation of teratomas showing differentiation into three germ layers as well as ES cells. Injection of iPS cells into the diploid blastocyte led to the generation of a chimera mouse. Thus, iPS cells that have the characteristic functions of ES cells may solve the problems related to clinical applications. Some of the reprogramming methods reported include: (i) nuclear transplant, (ii) cell fusion, (iii) reprogramming using cell extracts and (iv) direct reprogramming. However, the mechanism of cellular reprogramming is unclear. In the individual body derived from a fertilized egg, every cell has fundamentally the same original DNA sequence and genetic information, regardless of its ability to differentiate into various cell lineages. The regulation of gene expression is based on epigenetics, such as the gene silencing provoked by DNA methylation and the change in chromatin structure due to histone acetylation or methylation. In other words, the induction of pluripotency in somatic cells involves erasing the established epigenetic modification, leading to undifferentiated ES cells (3) . It is unclear how epigenome regulation, such as inducing epigenetic modifications such as DNA methylation and histone modification, maintains the pluripotency of ES cells and allows them to differentiate into multiple cell lineages at the same time. However, the induction of pluripotent stem cells from somatic cells (reprogramming) is expected to be applied to both regenerative medicine and also the treatment of various diseases, including cancers.
TECHNIQUES TO GENERATE PLURIPOTENT STEM CELLS
There are several methods of generating pluripotent stem cells (Fig. 1) . Some available methods are explained below.
NUCLEAR TRANSFER
Speman (4) first proposed nuclear transfer with a newt in 1938, which was unsuccessful. In 1952, Briggs and King (5) succeeded in producing the tadpole, the first cloned animal, from the cell nucleus of a frog in the blastocyst stage. For mammals, the first nuclear transfer-derived cloned sheep was generated in 1986 by transferring a blastomere nucleus from a four-to eight-cell sheep embryo to an enucleated unfertilized egg; in the following year, the cloned mouse was produced by transferring nuclei from eight-cell mouse embryos to enucleated two-cell embryos (6, 7) . In 1997, somatic cell clones were produced using the mammary cells of adult sheep (8) . In addition, a cloned mouse, goat, pig and rabbit were reported along with cloned cattle (9 -17) , and the cloned animals were produced successfully using nuclear transfer techniques with many types of somatic cells, including cumulus cells, leukocytes, hepatocytes, neuronal cells, myocytes, lymphocytes and germ cells (18 -20) . Nuclear 
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Methods for preparing iPS cells transfer reprograms the cell nuclei of differentiated somatic cells by transplanting them into an enucleated oocyte. In order to create a cloned embryo without using sperm after nuclear transfer, the egg was activated by electrical or chemical stimulation. The cloned embryo develops the blastocyst, from which ES cells are removed, and the somatic cells can produce the pluripotent and differentiated cells. In 2002, it was reported that an ES cell was produced by nuclear transfer from the tail of an immunodeficient mouse after one of the mutated alleles in the ES cells was repaired by homologous recombination. The repaired ES cells differentiated into blood stem cells and hematopoietic precursors were derived from the repaired ES cells by in vitro differentiation and engrafted into mutant mice (21) . However, an unfertilized egg must be procured for clinical applications and immunological rejection may occur due to genetic factors from the nuclei isolated from somatic cells and the oocyte. In 2007, it was reported that only 2 cells out of a total of 304 oocytes were successfully created as ES cells by nuclear transfer (22), suggesting a low induction efficiency.
CELL FUSION
Cell fusion is another reprogramming method. The somatic cell genome is highly reprogrammed in a syncytium where cell division occurs repeatedly with the nuclei of ES cells and somatic cells mixed (23, 24) ; therefore, it is supposed that ES cells are able to reprogram the somatic cells by deleting their properties and overwriting the somatic cell genome with the properties of ES cells (23) . The transcription factors Oct4 and Nanog, which act to maintain undifferentiated properties, are derived from the somatic cell genome fused with ES cell hybrids and reactivate themselves within 48 h (23, 25, 26) .
ES cell hybrids formed teratomas in immunodeficient mice and they generated chimera embryos after blastocyst injection, which demonstrates the pluripotency of ES cell hybrids (23, 24) . It has been reported that the pluripotent cells can also be generated from mice (23) and human beings (27, 28) through reprogramming using cell fusion. It is currently unknown whether the somatic cell nuclei can be reprogrammed by cell fusion with only the cytoplasmic elements of ES cells or if the nuclear elements are also needed. It is desirable to selectively remove only the chromosomes of ES cells from the fused nuclei, but it is technically difficult. Instead, a method has been planned to reject only the ES cell nuclei in a temporary heterokaryon state, just after the cell fusion, where the ES cell nuclei and the somatic cell nuclei exist independently (29) , but it will be a long time before this advanced technique is used in clinical applications.
REPROGRAMMING USING CELL EXTRACTS
Another reprogramming method inserts cell extracts, which are obtained from pluripotent stem cells such as ES cells, into somatic cells. As described in the previous section on 'Cell fusion', ES cells have a specific characteristic that reprograms the somatic cells. The cell extract is chemically isolated from ES cells and consists of reprogramming factors that enter into the somatic cells and induces their reprogramming. It was reported in 2005 that culturing HEK293 and NIH3T3 cells with the factors isolated from human embryonic carcinoma NCCIT cells increased the expression levels of undifferentiation markers, including Oct4, and that the cells could be induced to differentiate into neurogenic, adipogenic, osteogenic and endothelial lineages (30) . However, they could not be differentiated into three germ layers in vivo. Thus, this reprogramming method may be incomplete.
DIRECT REPROGRAMMING

REPROGRAMMING BY THE ADDITION OF TRANSCRIPTION FACTORS
In 2006, it was reported that four transcription factors (Oct3/4, Sox2, c-Myc and Klf4) were introduced into MEF to generate iPS cells (1) . The generated iPS cells showed gene expression of ES-cell markers such as Nanog and Oct3/4. In addition, a teratoma was formed by transferring iPS cells into the subcutaneous tissue of a nude mouse and cells were able to differentiate into the tissues of three germ layers. Furthermore, microinjection of these factors into a mouse blastocyst led to the production of a chimera mouse, indicating these were germline factors that were maintained in the next generation. These findings suggested that the pluripotency of these cells was equivalent to that of ES cells (31) . Since then, direct reprogramming has been widely studied by introducing these transcription factors or various other factors. The pluripotent stem cells are induced by various somatic cells, including fibroblasts, blood cells and keratinocytes (Table 1) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) .
It is unclear how the introduction of these transcription factors generates iPS cells equipped with the same functions of ES cells. Recent reports suggest that Oct3/4, Sox2 and Nanog may down-regulate the expression of genes involved in the induction of differentiation of cells to maintain their undifferentiated properties (46, 51) and all four factors (including c-Myc) cause the epigenetic changes, such as the chromatin modification and DNA methylation, that generate iPS cells. The promoter regions of Nanog, Oct3/4 and Fbx15 were reported to be demethylated in iPS cells as well as ES cells (1) .
On the other hand, the mice derived from these iPS cells have a high rate of tumor occurrence. c-Myc is one of the reprogramming factors and is known as an oncogene. In the process of reprogramming the somatic cells to iPS cells, the genes introduced by the retrovirus usually undergo silencing, but the c-Myc gene was found to be reactivated in the generated tumor (31) . The introduction of the three transcription factors (minus c-Myc) also successfully generated iPS cells and mice derived from Myc 2 iPS cells did not develop tumors during the study period (43) . However, the induction Jpn J Clin Oncol 2012;42 (9) 775 efficiency for reprogramming with just the three transcription factors (minus c-Myc) was ,1/10, which is much lower than when all four transcription factors were introduced. In 2011, there was a report of reprogramming by the addition of four transcription factors (Oct3/4, Sox2, Klf4 and Glis1) that had an induction efficiency that was equivalent to or higher than that observed with the other set of four transcription factors (including c-Myc); in addition, the problematic tumor formation induced by c-Myc was averted (41).
REPROGRAMMING BY THE ADDITION OF MICRORNAS
Approximately 1000 types of microRNAs (miRNAs), small RNAs consisting of an 18-to 24-nucleotide segment have been identified in humans. miRNA was first reported in 1993 (52) . After the RNA, featuring a pri-miRNA loop construction, is transcribed from DNA, pre-miRNA is created to export to the extranuclear part of the cell. Dicer cleaves miRNA 20 -25 nucleotides long in the cytoplasm, so that a miRNA-RISC complex is formed to connect to the 3 0 end untranslated regions and regulate gene expression. As the connection between miRNA and mRNA is incomplete, multiple genes can be controlled if there is more than one target gene.
The self-renewal and pluripotency of stem cells are regarded as essential functions. Past studies have identified some genes that are important for maintaining these functions. Abnormal pluripotency was reported in ES cells missing DGCR8 or Dicer (53, 54) ; therefore, they must be important in the biosynthetic pathway of miRNA. Our findings imply that miRNAs are important for the differentiation of ES cells. It is predicted that miRNAs, which are specifically expressed in ES cells and have reduced expression in already differentiated cells, play some role in the self-renewal ability and the maintenance of pluripotency. The mir-302s, -17s, -515s and mir-371 -373 clusters are increased, especially their expression levels, in ES cells; while miRNAs are reduced when the cells differentiate ( Fig. 2) (55,56) . The mir-302s cluster plays a serious role when pluripotent stem cells are generated using miRNA. Some researchers reported that the integration and introduction of the mir-302s cluster into the genome made it possible to generate specific pluripotent cells, like ES cells, from human skin cancer cells (57) . In recent years, the introduction of the mir-302/367 clusters has allowed iPS cells to be 776 Methods for preparing iPS cells generated efficiently (58) . Therefore, both transcription factors and miRNAs are able to generate pluripotent stem cells.
PROBLEMS WITH REPROGRAMMING METHODS USING A VIRUS VECTOR
Several studies showed that some reprogramming factors such as Oct3/4, Sox2, c-Myc, Klf4, Glis1, Nanog and Lin28 must be expressed in a stable state for at least 1 week to generate iPS cells. Thus, the reprogramming factors have to be integrated into the genomic DNA using a retrovirus or lentivirus vector. After iPS cells are generated, expression of these integrated exogenous genes seem to be down-regulated somewhat through silencing; yet, tumorigenesis is a major obstacle for clinical applications because there is a possibility that the oncogenes may be expressed and the tumor suppressor genes might be inactivated when integrating the exogenous genes. Several methods have been reported for generating iPS cells through use of a plasmid vector or adenovirus vector without integrating the exogenous genes into the host genome (Table 2 ) (36,59 -63) . There are still problems, including low induction efficiency, and the influence of the host genome cannot be completely excluded; however, it remains important to establish a method of generating iPS cells efficiently and stably without integrating in the future.
REPROGRAMMING WITHOUT INTEGRATING GENES INTO THE HOST GENOME OR USING GENOMIC DNA
In 2009, there was a report of reprogramming by inserting the Oct3/4, Sox2, c-Myc and Klf4 proteins, which were transcribed from human or mouse fibroblasts, into the cytoplasm (64) . This reprogramming method did not use a virus vector and genomic DNA, but it had a complicated technique and very low induction efficiency, which must be overcome for clinical applications.
In 2011, our laboratory reported a reprogramming method that enabled pluripotent stem cells to be produced using a non-viral vector and mature miRNAs (65) . To select candidate miRNAs for efficient reprogramming, we searched an array for miRNAs with expression levels that were increased in ES cells and iPS cells, but decreased in mouse adipose stem cells (mASCs). We preferentially used mASCs since it was reported in 2009 that the induction efficiency of pluripotent stem cells was more enhanced when four transcription factors were introduced in mASCs compared with fibroblasts (66) . The mASCs were transfected with three mature miRNAs (mir-200c, -302s and -369s) , selected based on their expression levels and pluripotent stem cells were generated. This avoided the problem of tumorigenesis that may occur when integrating the exogenous genes directly into the host genome.
TARGET GENES OF MIR-200C, -302S AND -369S
We searched the target genes of mir-200c using database search sites such as TargetScan and Sanger and found more than 700 genes. None of these genes were only controlled by mir-200c, but some important genes in reprogramming were detected among them. In particular, ZEB1/ZEB2 are reported to be epithelial -mesenchymal transaction (EMT) promoting factors (67) and are also important factors in the induction of pluripotent stem cells. ZEB1/ZEB2 are regulated by mir-200c, which regulates the EMT while promoting the mesenchymal -epithelial transaction, which is the first step in the induction of iPS cells (68) . In addition, mir-369s regulates both ZEB2-related transforming growth factor beta signaling and EMT (69) . There are reports that mir-302s plays a pivotal role in the self-renewal ability of pluripotent stem cells and the maintenance of pluripotency in ES cells (70) and that specific transcription factors occupy the promoter region of miRNAs, including mir-302, in pluripotent stem cells like ES cells and the transcription factors and miRNA act to maintain the functions of ES cells (71) . There are 100 target genes for mir-302s and 4 epigenetic regulatory factors [AOF1, AOF2 (KDM1 or LSD1), MECP1-p66 and MECP2] that are especially important in reprogramming and mir-302s activates the expression of these genes through demethylation in the promoter region of Nanog, Oct4 and Sox2. The activated Nanog, Oct4 and Sox2 increase not only their expression levels but also the level of mir-302s because its promoter is activated reversely. It is supposed that this positive feedback loop exists (72) and the cells are transfected with mature miRNA several times to maintain the increased expression of the transcription factors essential for reprogramming and to generate the pluripotent stem cells.
APPLICATION OF MIRNA REPROGRAMMING METHOD IN CANCER TREATMENT
After the leukemic stem cell was identified in 1997 (73) , many research studies focused on the identification of cancer stem cells. In 2006, the American Association for Cancer Research defined cancer stem cells as cells that exist in the tumor and have both the self-renewal activity and the ability to produce various origin-and-type cancer cells that construct is genetic, the essential difference between cells is supposed to be epigenetic (74). As described above, the reprogramming method using miRNA was performed based on epigenetic modifications. However, if the essential difference between cancer stem cells and other cancer cells is epigenetic, the reprogramming method using miRNA may play a great role in the treatment of cancer stem cells. In 2010, our laboratory introduced four transcription factors (Oct3/4, Sox2, C-Myc and Klf4) into cancer cells, successfully generating induced pluripotent cancer (iPC) cells that reduced malignancy, but there were safety problems that remain to be solved for clinical applications (75) . The iPC cells exhibited a separate differential potency from the original cancer cells. The introduced genes (Nanog, Rex1, Oct3/4, Sox2, Klf4 and c-Myc) had increased expression levels and ES cell surface markers (Ssea-4, Tra-1 -60, Tra-1 -81 and Tra-2 -49) were positive. Furthermore, the differentiation of iPC cells indicated an increase in anticancer drug sensitivity and a decrease in tumorigenic properties. Epigenetic analysis of the differentiated iPC cells showed an increase in the expression of the tumor suppressor gene p16 and demethylation in the promoter region of the genes.
The reprogramming of cancer cells through the introduction of transcription factors may lead to new cancer treatments, but safety problems exist in the clinical application due to reprogramming methods using virus vectors or in the integration of transcription factors into the host genome. Thus, we are now researching the possibility of reducing malignancy by using the reprogramming method utilizing miRNAs in cancer cells. To forward this goal, we should mention that a certain effectual delivery system is also essential to turn all cancer cells into iPC cells.
CONCLUSION
The direct reprogramming approach has great potential not only in regenerative medicine but also for the treatment of various diseases including cancer. In the future, reprogramming methods with the highest safety, efficiency and completion will be necessary for clinical applications.
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